Evidence map›Paper›PMID 27626687›Full record

ArticleOncotarget2016

New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells.

Jörg C Heinrich, Sainitin Donakonda, V Joachim Haupt, Petra Lennig, Yixin Zhang, Michael Schroeder

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Methoxybenzamide derivative of nimesulide from anti-fever to anti-cancer: Chemical characterization and cytotoxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Overcoming cancer therapeutic bottleneck by drug repurposing.Signal transduction and targeted therapy · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jörg C HeinrichBiotechnology Center, Technische Universität Dresden, 01307 Dresden, Germany.
Sainitin DonakondaBiotechnology Center, Technische Universität Dresden, 01307 Dresden, Germany.
V Joachim HauptBiotechnology Center, Technische Universität Dresden, 01307 Dresden, Germany.
Petra LennigB CUBE - Center for Molecular Bioengineering, Technische Universität Dresden, 01307 Dresden, Germany.
Yixin ZhangB CUBE - Center for Molecular Bioengineering, Technische Universität Dresden, 01307 Dresden, Germany.
Michael SchroederBiotechnology Center, Technische Universität Dresden, 01307 Dresden, Germany.
TU Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance is an important open problem in cancer treatment. In recent years, the heat shock protein HSP27 (HSPB1) was identified as a key player driving resistance development. HSP27 is overexpressed in many cancer types and influences cellular processes such as apoptosis, DNA repair, recombination, and formation of metastases. As a result cancer cells are able to suppress apoptosis and develop resistance to cytostatic drugs. To identify HSP27 inhibitors we follow a novel computational drug repositioning approach. We exploit a similarity between a predicted HSP27 binding site to a viral thymidine kinase to generate lead inhibitors for HSP27. Six of these leads were verified experimentally. They bind HSP27 and down-regulate its chaperone activity. Most importantly, all six compounds inhibit development of drug resistance in cellular assays. One of the leads - chlorpromazine - is an antipsychotic, which has a positive effect on survival time in human breast cancer. In summary, we make two important contributions: First, we put forward six novel leads, which inhibit HSP27 and tackle drug resistance. Second, we demonstrate the power of computational drug repositioning.

Indexed as

Antipsychotic AgentsApoptosisCell Line, TumorChlorpromazineComputational BiologyCytostatic AgentsDrug RepositioningDrug Resistance, NeoplasmHSP27 Heat-Shock ProteinsHumansMolecular Docking SimulationMolecular StructureNeoplasmsProtein BindingAntipsychotic AgentsChlorpromazineCytostatic AgentsHSP27 Heat-Shock Proteinsbinding siteBVDUdrug repositioningdrug repurposingHSPB1

Identifiers

PMID27626687
PMCPMC5356546
OpenAlexW2514692379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.